Selective NLRP3 Inflammasome Inhibitor MCC950 Suppresses Inflammation and Facilitates Healing in Vascular Materials
Advanced Science · 2023
DOI: 10.1002/advs.202300521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Angus J Grant und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Sciences, Faculty of Health and Medicine, Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia. Hauptthemen laut MEDLINE: Inflammasomes, NLR Family, Pyrin Domain-Containing 3 Protein. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Sydney Local Health District, NSW Health.
Abstract (Originalsprache)
Minimally invasive interventions using drug‐eluting stents or balloons are a first‐line treatment for certain occlusive cardiovascular diseases, but the major long‐term cause of failure is neointimal hyperplasia (NIH). The drugs eluted from these devices are non‐specific anti‐proliferative drugs, such as paclitaxel (PTX) or sirolimus (SMS), which do not address the underlying inflammation. MCC950 is a selective inhibitor of the NLRP3‐inflammasome, which drives sterile inflammation commonly observed in NIH. Additionally, in contrast to broad‐spectrum anti‐inflammatory drugs, MCC950 does not compromise global immune function due this selective activity. In this study, MCC950 is found to not impact the viability, integrity, or function of human coronary endothelial cells, in contrast to the non‐specific anti‐proliferative effects of PTX and SMS. Using an in vitro model of NLRP3‐mediated inflammation in murine macrophages, MCC950 reduced IL‐1 β expression, which is a key driver of NIH. In an in vivo mouse model of NIH in vascular grafts, MCC950 significantly enhanced re‐endothelialization and reduced NIH compared to PTX or SMS. These findings show the effectiveness of a targeted anti‐inflammatory drug‐elution strategy with significant implications for cardiovascular device intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medical Sciences, Faculty of Health and Medicine, Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia.
- Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW, 2006, Australia.
ORCID-Profile: Steven G Wise
Förderung
- National Health and Medical Research Council
- Sydney Local Health District
- NSW Health
- NSW Cardiovascular Early-Mid Research Grant
- ARC Future Fellow
- National Heart Foundation of Australia
- NSW Ministry of Health
Zitieren
APA
Grant, A. J., Yang, N., Moore, M. J., Lam, Y. T., Michael, P. L., Chan, A. H. P., Santos, M., Rnjak-Kovacina, J., Tan, R. P., & Wise, S. G. (2023). Selective NLRP3 Inflammasome Inhibitor MCC950 Suppresses Inflammation and Facilitates Healing in Vascular Materials. Advanced Science. https://doi.org/10.1002/advs.202300521
Vancouver
Grant AJ, Yang N, Moore MJ, Lam YT, Michael PL, Chan AHP, et al. Selective NLRP3 Inflammasome Inhibitor MCC950 Suppresses Inflammation and Facilitates Healing in Vascular Materials. Advanced Science. 2023. doi:10.1002/advs.202300521
BibTeX
@article{Grant2023,
author = {Grant, Angus J and Yang, Nianji and Moore, Matthew J and Lam, Yuen Ting and Michael, Praveesuda L and Chan, Alex H P and Santos, Miguel and Rnjak-Kovacina, Jelena and Tan, Richard P and Wise, Steven G},
title = {Selective NLRP3 Inflammasome Inhibitor MCC950 Suppresses Inflammation and Facilitates Healing in Vascular Materials},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202300521}
}
EUVIMED